The sodium-glucose co-transporter 2 or sodium-glucose linked transporter 2 (SGLT2)-inhibitors (SGLT2-Is), also named gliflozins, are a relatively novel class of oral agents used in the treatment of type 2 diabetes mellitus (T2DM). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.